when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Lead Candidate · news · pharmadog

← back to Lead Candidate

News mentioning Lead Candidate

70 stories

2dFoghorn cuts 40% of workforcebiospace

2dNovartis wagers almost $8B on a Chinese biotech’s RNA drugsbiopharma dive

12d2026 IPO blitz continues with 4 new biotech filingsbiospace

14dTelix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’biopharma dive

14dCiting Replimune approval, experts say localized cancer meds could redefine carebiospace

18dGoa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcoholfiercebiotech

20dSionna lays off 46% of workforce in strategic shift after cystic fibrosis trial failfiercebiotech

21dCellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonfiercebiotech

23dAlzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drugendpoints

25dKura spins diabetes work into a Lilly-backed biotech startupbiopharma dive

26dA new immuno-oncology play raises $225M for a next-generation drugbiopharma dive

26dCaspian launches with $50M, Lilly support to advance disease-modifying diabetes betbiospace

27dBrainChild Bio targets deadly pediatric brain cancer with $116M series Abiospace

27dBrainChild hauls in $116M to make cell therapies for childhood brain cancersbiopharma dive

27dBrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancerfiercebiotech

Sep 1, 26From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Applefiercebiotech

Sep 1, 26Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?fiercebiotech

Aug 31, 26Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodiesfiercebiotech

Aug 28, 26BioXcel files for bankruptcy, will sell assets to Teva for up to $125Mbiospace

Aug 28, 26AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyondfiercebiotech

Aug 27, 26Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushfiercebiotech

Aug 26, 26Biohaven strikes $795M deal for commercial partner in epilepsyendpoints

Aug 25, 26After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformfiercebiotech

Aug 18, 26BioMarin acquires experimental drug for rare bone disorder in $275M dealbiopharma dive

Aug 17, 26EyePoint plummets on pivotal data for main drugbiopharma dive

Aug 17, 26Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsfiercebiotech

Aug 14, 26Abcuro gets $66M for Phase 3 in muscle-weakening conditionendpoints

Aug 14, 26MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlontaendpoints

Aug 14, 26Skye and Redx form new entity with $125M to advance fibrosis assetsfiercebiotech

Aug 12, 26Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillfiercebiotech

← prevpage 1 of 3next →